Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2026-03-03 @ 12:35 AM
Study NCT ID:
NCT05397834
Status:
UNKNOWN
Last Update Posted:
2022-05-31
First Post:
2022-05-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Sponsor:
Respirent Pharmaceuticals Co Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-11
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-25
First Submit QC Date:
None
Study First Post Date:
2022-05-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-25
Last Update Post Date:
2022-05-31
Last Update Post Date Type:
ACTUAL